Merck and Huma Therapeutics launch innovative app to support bladder cancer patients

London headquartered Huma Therapeutics, together with Germany's Merck KGaA, has announced the launch of their innovative bladder cancer treatment companion app in the United Kingdom. This collaboration underscores Merck KGaA, Darmstadt, Germany and Huma's joint commitment to advancing patient-directed care and empowering patients and caregivers throughout their cancer care pathway.

UK-based patient organisations and specialist cancer care centres were involved in and piloting the bladder cancer treatment journey app in advance of the launch.

The bladder cancer treatment companion app developed by Huma and Merck KGaA, is designed to support patients and caregivers in navigating the complexities of bladder cancer treatment by providing a reliable source of information and support throughout the treatment journey. The app aims to provide patients with improved understanding of their treatment, better conversations with their care team as well as self-tracking of their health state. The app will also enable patients to raise awareness of available holistic care services, encourage connection with personal support network and expectation management and motivation through content.

Joachim Chan, a consultant clinical oncologist at the Clatterbridge Cancer Centre in Liverpool said, "Although there is a wealth of knowledge available to patients through various websites, patients may understandably want a reliable source of information through a single portal. Merck KGaA, Darmstadt, Germany has collaborated with various stakeholders to create an app to this end.